3.97  0.21 (5.59%)		11-28 13:00
Open: 3.81 High: 3.97 Volume: 28,152		Pre. Close: 3.76 Low: 3.76 Market Cap: 338(M)

Short term
Mid term
Targets	6-month :	5.25	1-year :	6.13
Resists	First :	4.5	Second :	5.25
Pivot price	3.79
Supports	First :	3.83	Second :	3.43
MAs	MA(5) :	3.81	MA(20) :	3.83
	MA(100) :	3.65	MA(250) :	3.25
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	65.6	D(3) :	56.1
RSI	RSI(14): 53
52-week	High :	4.69	Low :	2.29

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ DRTS ] has closed below upper band by 18.9%. Bollinger Bands are 9.6% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	4.05 - 4.07	4.07 - 4.09
Low:	3.66 - 3.68	3.68 - 3.7
Close:	3.7 - 3.74	3.74 - 3.77

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Thu, 20 Nov 2025
Alpha Tau Announces Third Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire

Thu, 20 Nov 2025
Alpha Tau Medical Reports Q3 2025 Results and Advances in Cancer Therapy - TipRanks

Thu, 20 Nov 2025
Alpha Tau Medical Reports Q3 2025 Progress and Financials - TipRanks

Tue, 11 Nov 2025
Alpha Tau to Participate at Jefferies Global Healthcare Conference in London - GlobeNewswire

Tue, 21 Oct 2025
Alpha Tau Secures Radioactive Material License for New Hampshire Facility - TipRanks

Tue, 21 Oct 2025
Alpha Tau (Nasdaq: DRTS) receives NH radioactive material license, targets 2026 output - Stock Titan

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Neutral
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	85 (M)
Shares Float	57 (M)
Held by Insiders	32.7 (%)
Held by Institutions	2.5 (%)
Shares Short	90 (K)
Shares Short P.Month	102 (K)

EPS	-0.48
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1.01
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-22.7 %
Return on Equity (ttm)	-43.9 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-0.43
Qtrly Earnings Growth	0 %
Operating Cash Flow	-22 (M)
Levered Free Cash Flow	-18 (M)

PE Ratio	-8.28
PEG Ratio	0
Price to Book value	3.89
Price to Sales	0
Price to Cash Flow	-15.64

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.